Literature DB >> 25564405

Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.

Stefano Iacovelli1, Eva Hug2, Sara Bennardo1, Marcus Duehren-von Minden2, Stefania Gobessi1, Andrea Rinaldi3, Mirza Suljagic1, Daniel Bilbao4, Giulia Bolasco4, Julia Eckl-Dorna5, Verena Niederberger5, Francesco Autore6, Simona Sica6, Luca Laurenti6, Hongsheng Wang7, Richard J Cornall8, Stephen H Clarke9, Carlo M Croce10, Francesco Bertoni11, Hassan Jumaa12, Dimitar G Efremov1.   

Abstract

Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy characterized by a highly variable course and outcome. The disease is believed to be driven by B-cell receptor (BCR) signals generated by external antigens and/or cell-autonomous BCR interactions, but direct in vivo evidence for this is still lacking. To further define the role of the BCR pathway in the development and progression of CLL, we evaluated the capacity of different types of antigen/BCR interactions to induce leukemia in the Eμ-TCL1 transgenic mouse model. We show that cell autonomous signaling capacity is a uniform characteristic of the leukemia-derived BCRs and represents a prerequisite for CLL development. Low-affinity BCR interactions with autoantigens generated during apoptosis are also positively selected, suggesting that they contribute to the pathogenesis of the disease. In contrast, high-affinity BCR interactions are not selected, regardless of antigen form or presentation. We also show that the capacity of the leukemic cells to respond to cognate antigen correlates inversely with time to leukemia development, suggesting that signals induced by external antigen increase the aggressiveness of the disease. Collectively, these findings provide in vivo evidence that the BCR pathway drives the development and can influence the clinical course of CLL.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25564405      PMCID: PMC4351506          DOI: 10.1182/blood-2014-07-587790

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

Review 1.  Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells.

Authors:  Dimitar G Efremov; Stefania Gobessi; Pablo G Longo
Journal:  Autoimmun Rev       Date:  2007-03-28       Impact factor: 9.754

2.  Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.

Authors:  Roberta Bichi; Susan A Shinton; Eric S Martin; Anatoliy Koval; George A Calin; Rossano Cesari; Giandomenico Russo; Richard R Hardy; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

3.  Impaired clearance of apoptotic cells induces the activation of autoreactive anti-Sm marginal zone and B-1 B cells.

Authors:  Ye Qian; Hongsheng Wang; Stephen H Clarke
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

4.  Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.

Authors:  Olivier Hermine; François Lefrère; Jean-Pierre Bronowicki; Xavier Mariette; Katayoun Jondeau; Virginie Eclache-Saudreau; Béatrice Delmas; Françoise Valensi; Patrice Cacoub; Christian Brechot; Bruno Varet; Xavier Troussard
Journal:  N Engl J Med       Date:  2002-07-11       Impact factor: 91.245

Review 5.  Positive selection focuses the VH12 B-cell repertoire towards a single B1 specificity with survival function.

Authors:  Hongsheng Wang; Stephen H Clarke
Journal:  Immunol Rev       Date:  2004-02       Impact factor: 12.988

6.  Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia.

Authors:  Stuart Lanham; Terry Hamblin; David Oscier; Rachel Ibbotson; Freda Stevenson; Graham Packham
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

7.  Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.

Authors:  Ingo Ringshausen; Folker Schneller; Christian Bogner; Susanne Hipp; Justus Duyster; Christian Peschel; Thomas Decker
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113

8.  Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Liguang Chen; George Widhopf; Lang Huynh; Laura Rassenti; Kanti R Rai; Arthur Weiss; Thomas J Kipps
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

9.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

10.  The cellular location of self-antigen determines the positive and negative selection of autoreactive B cells.

Authors:  Helen Ferry; Margaret Jones; David J Vaux; Ian S D Roberts; Richard J Cornall
Journal:  J Exp Med       Date:  2003-11-03       Impact factor: 14.307

View more
  27 in total

1.  Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling.

Authors:  Daphne R Friedman; Eross Guadalupe; Alicia Volkheimer; Joseph O Moore; J Brice Weinberg
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

2.  Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice.

Authors:  Chih-Hang Tang; Shiun Chang; Ayumi Hashimoto; Yi-Ju Chen; Chang Won Kang; Anthony R Mato; Juan R Del Valle; Dmitry I Gabrilovich; Chih-Chi Hu
Journal:  Cancer Immunol Res       Date:  2018-04-12       Impact factor: 11.151

3.  Inhibition of reactive oxygen species limits expansion of chronic lymphocytic leukemia cells.

Authors:  B Yigit; N Wang; S-S Chen; N Chiorazzi; C Terhorst
Journal:  Leukemia       Date:  2017-07-28       Impact factor: 11.528

4.  Another step forward in the 20-year history of IGHV mutations in chronic lymphocytic leukemia.

Authors:  Ilaria Del Giudice; Robin Foà
Journal:  Haematologica       Date:  2019-02       Impact factor: 9.941

5.  Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice.

Authors:  Viktoria Kohlhas; Michael Hallek; Phuong-Hien Nguyen
Journal:  Blood Adv       Date:  2020-12-22

6.  Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures.

Authors:  Harvey E Johnston; Matthew J Carter; Kerry L Cox; Melanie Dunscombe; Antigoni Manousopoulou; Paul A Townsend; Spiros D Garbis; Mark S Cragg
Journal:  Mol Cell Proteomics       Date:  2017-01-04       Impact factor: 5.911

7.  Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma.

Authors:  Michael Fichtner; Elmar Spies; Henning Seismann; Kristoffer Riecken; Niklas Engels; Barbara Gösch; Judith Dierlamm; Helwe Gerull; Peter Nollau; Wolfram Klapper; Martin Dreyling; Mascha Binder; Martin Trepel
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

8.  Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.

Authors:  Elisa Ten Hacken; Mariela Sivina; Ekaterina Kim; Susan O'Brien; William G Wierda; Alessandra Ferrajoli; Zeev Estrov; Michael J Keating; Thomas Oellerich; Cristina Scielzo; Paolo Ghia; Federico Caligaris-Cappio; Jan A Burger
Journal:  J Immunol       Date:  2016-08-17       Impact factor: 5.422

9.  The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.

Authors:  J Wakim; E Arman; S Becker-Herman; M P Kramer; E Bakos; I Shachar; A Elson
Journal:  Oncogene       Date:  2017-02-06       Impact factor: 9.867

10.  Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.

Authors:  Nakhle S Saba; Delong Liu; Sarah E M Herman; Chingiz Underbayev; Xin Tian; David Behrend; Marc A Weniger; Martin Skarzynski; Jennifer Gyamfi; Lorena Fontan; Ari Melnick; Cliona Grant; Mark Roschewski; Alba Navarro; Sílvia Beà; Stefania Pittaluga; Kieron Dunleavy; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2016-04-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.